Agata Lewandowska, Dorota Borowicz, Grzegorz Bielęda, Oliwia Nowotka, Maksymilian Kazior, Justyna Krupka, Marek Kanikowski, Maciej Kozak
{"title":"不同厂家设计的I-125植入物在前列腺近距离治疗中的点剂量计量学验证。","authors":"Agata Lewandowska, Dorota Borowicz, Grzegorz Bielęda, Oliwia Nowotka, Maksymilian Kazior, Justyna Krupka, Marek Kanikowski, Maciej Kozak","doi":"10.5603/rpor.102819","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The purpose of this study is to determine the effect of the type of I-125 radioactive source on dose distribution in the planning process of ultra-low dose rate (uLDR) prostate brachytherapy.</p><p><strong>Material and methods: </strong>7 patients who had undergone brachytherapy in our center were included in the study. Dose in five geometrical points were analyzed for 12 types of implants that are available on the market. The plans were originally calculated for S17plus implant model (Eckert & Ziegler Medical). Point dose calculations were performed using RadCalc (LAP) software.</p><p><strong>Results: </strong>The differences in doses for individual points were significant. The largest differences were observed at the point located in the center of the patients' urethra and between BestMedical 2301 (highest doses for each point) and IsoStar (lowest doses) implants.</p><p><strong>Conclusions: </strong>The choice of implant manufacturer strongly influences what dose distribution will be obtained for the prostate. It is possible to obtain satisfactory plans that meet the dosimetric criteria for each type of implant, but the positioning of each source will vary significantly.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 5","pages":"588-599"},"PeriodicalIF":1.2000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698560/pdf/","citationCount":"0","resultStr":"{\"title\":\"Dosimetric verification of point doses for I-125 implants designed by different manufacturers in prostate brachytherapy.\",\"authors\":\"Agata Lewandowska, Dorota Borowicz, Grzegorz Bielęda, Oliwia Nowotka, Maksymilian Kazior, Justyna Krupka, Marek Kanikowski, Maciej Kozak\",\"doi\":\"10.5603/rpor.102819\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The purpose of this study is to determine the effect of the type of I-125 radioactive source on dose distribution in the planning process of ultra-low dose rate (uLDR) prostate brachytherapy.</p><p><strong>Material and methods: </strong>7 patients who had undergone brachytherapy in our center were included in the study. Dose in five geometrical points were analyzed for 12 types of implants that are available on the market. The plans were originally calculated for S17plus implant model (Eckert & Ziegler Medical). Point dose calculations were performed using RadCalc (LAP) software.</p><p><strong>Results: </strong>The differences in doses for individual points were significant. The largest differences were observed at the point located in the center of the patients' urethra and between BestMedical 2301 (highest doses for each point) and IsoStar (lowest doses) implants.</p><p><strong>Conclusions: </strong>The choice of implant manufacturer strongly influences what dose distribution will be obtained for the prostate. It is possible to obtain satisfactory plans that meet the dosimetric criteria for each type of implant, but the positioning of each source will vary significantly.</p>\",\"PeriodicalId\":47283,\"journal\":{\"name\":\"Reports of Practical Oncology and Radiotherapy\",\"volume\":\"29 5\",\"pages\":\"588-599\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-12-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698560/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reports of Practical Oncology and Radiotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5603/rpor.102819\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reports of Practical Oncology and Radiotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/rpor.102819","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Dosimetric verification of point doses for I-125 implants designed by different manufacturers in prostate brachytherapy.
Background: The purpose of this study is to determine the effect of the type of I-125 radioactive source on dose distribution in the planning process of ultra-low dose rate (uLDR) prostate brachytherapy.
Material and methods: 7 patients who had undergone brachytherapy in our center were included in the study. Dose in five geometrical points were analyzed for 12 types of implants that are available on the market. The plans were originally calculated for S17plus implant model (Eckert & Ziegler Medical). Point dose calculations were performed using RadCalc (LAP) software.
Results: The differences in doses for individual points were significant. The largest differences were observed at the point located in the center of the patients' urethra and between BestMedical 2301 (highest doses for each point) and IsoStar (lowest doses) implants.
Conclusions: The choice of implant manufacturer strongly influences what dose distribution will be obtained for the prostate. It is possible to obtain satisfactory plans that meet the dosimetric criteria for each type of implant, but the positioning of each source will vary significantly.
期刊介绍：
Reports of Practical Oncology and Radiotherapy is an interdisciplinary bimonthly journal, publishing original contributions in clinical oncology and radiotherapy, as well as in radiotherapy physics, techniques and radiotherapy equipment. Reports of Practical Oncology and Radiotherapy is a journal of the Polish Society of Radiation Oncology, the Czech Society of Radiation Oncology, the Hungarian Society for Radiation Oncology, the Slovenian Society for Radiotherapy and Oncology, the Polish Study Group of Head and Neck Cancer, the Guild of Bulgarian Radiotherapists and the Greater Poland Cancer Centre, affiliated with the Spanish Society of Radiotherapy and Oncology, the Italian Association of Radiotherapy and the Portuguese Society of Radiotherapy - Oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
